EPIDUO FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPIDUO FORTE (EPIDUO FORTE).
Adapalene binds to retinoic acid nuclear receptors (RARβ/γ) modulating gene expression, reducing comedogenesis and inflammation. Benzoyl peroxide oxidizes bacterial proteins and produces reactive oxygen species, killing Propionibacterium acnes and reducing follicular hyperkeratinization.
| Metabolism | Adapalene is extensively metabolized in the liver via cytochrome P450 enzymes (primarily CYP2C9, CYP2C8, and CYP3A4) to form glucuronide conjugates, with negligible systemic absorption after topical application. Benzoyl peroxide is oxidized to benzoic acid on the skin and may be further conjugated with glycine to form hippuric acid, with minimal hepatic metabolism. |
| Excretion | Adapalene: primarily excreted via biliary elimination (~75% recovered in feces, mainly as metabolites), with renal excretion accounting for <10% unchanged. Benzoyl peroxide: degraded to benzoic acid, which is conjugated and excreted renally; ~60-70% of a topical dose is excreted as benzoic acid metabolites in urine. |
| Half-life | Adapalene: terminal half-life of 0.5-2 hours in dermis, but clinical effects persist due to receptor binding; systemic half-life after topical application is biphasic with a long terminal phase of ~7-10 hours for low levels. Benzoyl peroxide: not systemically absorbed; half-life not applicable. |
| Protein binding | Adapalene: >99% bound to plasma proteins (mainly albumin). Benzoyl peroxide: not systemically absorbed; protein binding not applicable. |
| Volume of Distribution | Adapalene: Vd is 0.2-0.5 L/kg, indicating distribution into tissues. Benzoyl peroxide: not applicable due to lack of systemic absorption. |
| Bioavailability | Topical: systemic absorption of adapalene is minimal (<0.5% of applied dose); benzoyl peroxide is minimally absorbed (<5% as benzoic acid). Bioavailability via topical route is negligible; drug acts locally. |
| Onset of Action | Topical: clinical improvement in acne comedones and inflammatory lesions is typically observed within 2-4 weeks of regular use, with maximal effect after 8-12 weeks. |
| Duration of Action | Topical: effect lasts for at least 24 hours after application; continuous use required. Benzoyl peroxide provides rapid antimicrobial effect, but duration of action on Cutibacterium acnes is sustained with daily dosing. |
Apply a pea-sized amount to affected areas once daily in the evening; topical gel, 0.3% adapalene / 2.5% benzoyl peroxide.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required; pharmacokinetics not studied in renal impairment. |
| Liver impairment | No dose adjustment required; pharmacokinetics not studied in hepatic impairment. |
| Pediatric use | Approved for ages 9 years and older; same adult dose (pea-sized amount once daily). |
| Geriatric use | No specific adjustments; elderly patients may have more sensitive skin; use caution and consider lower application frequency. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EPIDUO FORTE (EPIDUO FORTE).
| Breastfeeding | Adapalene: Unknown if excreted in human milk; minimal systemic absorption (0.8-1.5% of applied dose). Benzoyl peroxide: Metabolized to benzoic acid, excreted in milk; low risk. M/P ratio not established. Caution; avoid application to breast area. |
| Teratogenic Risk | Epiduo Forte contains adapalene (Category C) and benzoyl peroxide (Category C). Adapalene: Animal studies show teratogenic effects at topical doses 3-50 times MRHD; no adequate human studies. Avoid use during pregnancy, especially first trimester. Benzoyl peroxide: No evidence of teratogenicity in animal studies; limited human data. Risk cannot be excluded. Use only if clearly needed. |
■ FDA Black Box Warning
None.
| Common Effects | Erythema skin redness Burning sensation Scaling Stinging sensation |
| Serious Effects |
["Hypersensitivity to adapalene, benzoyl peroxide, or any component of the formulation","Severe acne with pustules or deep cysts (relative)"]
| Precautions | ["Avoid contact with eyes, lips, and mucous membranes","May cause photosensitivity, use sunscreen and protective clothing","Local skin reactions (erythema, scaling, dryness, stinging, burning) are common, especially during initial weeks","Do not apply to cuts, abrasions, or eczematous skin","May bleach hair or colored fabrics","Not for oral or ophthalmic use","Use during pregnancy only if clearly needed (Adapalene Category C, Benzoyl peroxide Category C)"] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Advise pregnancy testing before initiation if pregnancy potential. Monitor for maternal skin irritation. Inadvertent use requires prenatal care standard. |
| Fertility Effects | Adapalene: Animal studies show no effect on fertility at oral doses up to 20 mg/kg/day. Benzoyl peroxide: No fertility studies. No known human fertility impairment. |